The FDA on July 29 approved GlaxoSmithKline’s Nucala for the treatment of chronic rhinosinusitis with nasal polyps, making it the first IL-5 inhibitor in its class. The biologic will have to face off against Sanofi and Regeneron’s Dupixent, which was approved for nasal polyps in 2019. Under the pharmacy benefit, Dupixent holds preferred status (with utilization management restrictions applied in most cases) for 38% of all covered lives. Overall, it holds covered or better status for 73% of lives.

SOURCE: MMIT Analytics, as of 8/2/21